Porton Fine Chemicals Ltd (300363) - Total Liabilities
Based on the latest financial reports, Porton Fine Chemicals Ltd (300363) has total liabilities worth CN¥3.09 Billion CNY (≈ $451.95 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Porton Fine Chemicals Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Porton Fine Chemicals Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Porton Fine Chemicals Ltd (300363) investment intensity to see how much of total assets are deployed in long-term investments.
Porton Fine Chemicals Ltd Competitors by Total Liabilities
The table below lists competitors of Porton Fine Chemicals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sanbo Hospital Management Group Ltd. A
SHE:301293
|
China | CN¥1.06 Billion |
|
1st Source Corporation
NASDAQ:SRCE
|
USA | $7.74 Billion |
|
Tecan Group AG
SW:TECN
|
Switzerland | CHF656.74 Million |
|
Goodyear Tire & Rubber Co
NASDAQ:GT
|
USA | $15.29 Billion |
|
Encore Capital Group Inc
NASDAQ:ECPG
|
USA | $4.42 Billion |
|
SoftwareONE Holding AG
SW:SWON
|
Switzerland | CHF5.81 Billion |
|
Photronics Inc
NASDAQ:PLAB
|
USA | $237.37 Million |
|
Ratnamani Metals & Tubes Limited
NSE:RATNAMANI
|
India | Rs11.80 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Porton Fine Chemicals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 300363 current and non-current assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Porton Fine Chemicals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Porton Fine Chemicals Ltd (2009–2024)
The table below shows the annual total liabilities of Porton Fine Chemicals Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.40 Billion ≈ $498.25 Million |
+3.68% |
| 2023-12-31 | CN¥3.28 Billion ≈ $480.57 Million |
-10.56% |
| 2022-12-31 | CN¥3.67 Billion ≈ $537.33 Million |
+54.55% |
| 2021-12-31 | CN¥2.38 Billion ≈ $347.68 Million |
+115.27% |
| 2020-12-31 | CN¥1.10 Billion ≈ $161.51 Million |
+23.85% |
| 2019-12-31 | CN¥891.16 Million ≈ $130.41 Million |
-40.24% |
| 2018-12-31 | CN¥1.49 Billion ≈ $218.21 Million |
+6.60% |
| 2017-12-31 | CN¥1.40 Billion ≈ $204.70 Million |
-6.83% |
| 2016-12-31 | CN¥1.50 Billion ≈ $219.70 Million |
+25.13% |
| 2015-12-31 | CN¥1.20 Billion ≈ $175.58 Million |
+22.37% |
| 2014-12-31 | CN¥980.53 Million ≈ $143.48 Million |
+88.69% |
| 2013-12-31 | CN¥519.67 Million ≈ $76.04 Million |
+12.16% |
| 2012-12-31 | CN¥463.32 Million ≈ $67.80 Million |
+41.13% |
| 2011-12-31 | CN¥328.30 Million ≈ $48.04 Million |
+10.46% |
| 2010-12-31 | CN¥297.20 Million ≈ $43.49 Million |
+33.30% |
| 2009-12-31 | CN¥222.95 Million ≈ $32.62 Million |
-- |
About Porton Fine Chemicals Ltd
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more